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1. Introduction
Malignant melanoma cells are incredibly hardy, stemming from their intrinsic defensive
nature. These cells inherit unique characteristics, which allowed their non-malignant prede‐
cessors, melanocytes, to survive solar ultraviolet radiation and simultaneously provide
protection to neighboring cells. Most other cell types would die after such harsh exposure.
Unsurprisingly, melanoma cells, which survive ultraviolet radiation, are intrinsically resistant
to most chemotherapy.
Although there are numerous molecular reasons for this reality, herein we focus on the causal
role of autotaxin (ATX) in melanoma. ATX is a 125 kDa glycoprotein enzyme that was initially
discovered in the serum-free medium of A2058 human melanoma cells by Stracke et al. in 1992
[1] (Figure 1). Today, we know much more about this glycoprotein enzyme and how it affects
melanoma. Indeed, ATX is highly overexpressed among primary melanomas and metastatic
melanomas, in comparison to melanoma in situ and in normal skin [2].
In fact, “autotaxin” derived its name based on its initial property as an “autocrine motility
factor”. The rationale is that A2058 melanoma cells secrete ATX into culture medium and then
respond to it with self-stimulated random and directed motility. Even though the amount of
ATX in conditioned medium is less than 0.005% of total protein, only miniscule amounts,
detected in picomolar and nanomolar concentrations, are needed to promote motility. [1] This
suggests a large role for a low-abundant secreted enzyme.
There are five alternatively-spliced isoforms of ATX that are catalytically active [3,4]. The
original ATX protein described in 1992 is termed ATXα, whereas the most abundant isoform
is ATXβ and is the same isoform responsible for plasma lysoPLD activity [5]. Full length ATX
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is synthesized as a pre-proenzyme and is secreted by the classical secretory pathway [6,7].
Secreted ATX binds to cell surface integrin or heparan sulfates through its somatomedin-B-
like (SMB) domain. This surface binding is believed to localize LPA production adjacent to
LPA receptors [8-12].
Figure 1. Major milestones in autotaxin (ATX) research. After the discovery of ATX in the conditioned medium of
melanoma cells, it was not until a decade later that the enzyme was connected to lysophosphatidate. The elucidation of
the crystal structure by two different groups caused a surge of novel inhibitors.
2. Multiple functions of ATX
In addition to the ability of ATX to stimulate motility, ATX also has ATPase, phosphodiesterase
and ATP pyrophosphatase activities [13]. In other words, ATX releases nucleoside-5’-mono‐
phosphates from phosphodiester and pyrophosphate bonds [14], which is why it belongs to
the family of ENPP (ectonucleotide pyrophosphatase/ phosphodiesterase) enzymes with
ENPP1/PC-1, ENPP3/B10 [15], ENPP4 [14,16], ENPP6 [17], ENPP7 [18], and is also named
ENPP2 (Table 1). Interestingly, all of the phosphodiesterase catalytic activity of ATX resides
in one amino acid, threonine 210. Losing this phosphorylatable residue in the catalytic site
results in a loss of phosphodiesterase activity and motility, but not ATP binding [19]. Theo‐
retically, GTP, NAD, FAD, AMP and PPi are all susceptible to hydrolysis by ATX. However,
the preferred substrate for ATX is lysophosphatidylcholine (LPC), which it converts to
lysophosphatidate (LPA) (Figure 2). Since LPC concentrations in human plasma are greater
than 200 µM, this should outcompete the hydrolysis of nucleotide phosphates and pyrophos‐
phate, which are present in much lower concentrations.
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Enzyme Major Functions Disease Association
ENPP1 / PC-1 Insulin signaling, glucose import, bone mineralization,immune response Diabetes, obesity, stroke
ENPP2 / ATX Vasculature formation, neural development, catalyzeslysophosphatidate production
Cancer, obesity, pulmonary fibrosis,
arthritis, asthma, neuropathic pain,
liver and colonic disorders
ENPP3 / B10 Basophil activation biomarker Asthma, allergic reactions
ENPP4 Blood coagulant Stroke
ENPP5 Putative neural glycoprotein
ENPP6 Choline-specific hydrolysis of LPC, GPC and SPC
ENPP7 Alkaline sphingomyelinase
Table 1. Comparison between enzymes among the Ectonucleotide Pyrophosphatase/ Phosphodiesterase (ENPP)
family
Figure 2. Autotaxin (ATX) catalyzes the biosynthesis of lysophosphatidiate (LPA). Since the lysophosphatidylcholine
(LPC) concentrations in human circulation are >200 µM, ATX has abundantly available lipids to produce LPA. ATX
hydrolyzes the choline head group from LPC to yield LPA. As a consequence of LPA signaling on cells, a multitude of
various responses result, including motility, viability, growth, proliferation and contraction.
The ability of ATX to stimulate motility in melanoma cells can be modulated by chemical
methods and genetic engineering. For example, ATX-meditated motility is inhibited by the
PI3K inhibitors, wortmannin and LY294002, along with the catalytically inactive mutant of
PI3K, PI3KK832R [20]. In addition, ras-transformed NIH3T3 cells become more motile and
invasive in the presence of ATX. These cells also show enhanced colony formation in soft agar
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in vitro and produce significantly larger and metastatic tumors in vivo [21]. This suggests that
while ATX alone may be insufficient to transform cells to a malignant phenotype, the presence
of ATX significantly enhances malignant transformation among ‘primed’ cells.
3. Role as the main enzyme for the generation of extracellular LPA
The majority of LPA in the circulation is generated by ATX from the abundant LPC (>200 µM
in human plasma) in the circulation. In fact, LPC is the major plasma phospholipid and it is
bound to albumin [22]. Extracellular LPC is derived from two major routes of metabolism. The
first is through the action of lecithin:cholesterol acyltransferase, which is present in plasma
high-density lipoproteins. Lecithin:cholesterol acyltransferase, preferentially transfers
unsaturated fatty acids from postion-2 of phosphatidylcholine to cholesterol, producing
cholesterol ester and a mainly saturated LPC. However, a large proportion of circulating LPC
is polyunsaturated [22] and this indicates another route for the production of extracellular
LPC. Part of the polyunsaturated LPC is derived from secretion by hepatocytes, but it is
possible that other cell types could produce polyunsaturated LPC. Since hepatocytes secrete
a large quantity of arachidonoyl-LPC [22-26], it was originally postulated that this might
represent a novel transport system for delivering choline and polyunsaturated fatty acids to
the brain [22]. Although, this could still be true, we now know that LPC is an important
substrate for ATX and that this is the major route for the production of extracellular LPA [27].
This predominant role of ATX in generating LPA is confirmed by circulating LPA concentra‐
tions that are 50% of normal levels among ATX heterozygous mice for a null-mutation for ATX
[28,29]. Also, ATX inhibition produces a rapid decrease in plasma LPA of >95% [30-32]. The
effects of ATX inhibition are more dramatic for the unsaturated species [33]. This is compatible
with the substrate preference of ATX for unsaturated and polyunsaturated LPCs [34]. The
crystal structures of ATX:LPA complexes show a hydrophobic pocket in the catalytic domain
that is slightly U-shaped. This accommodates the kinked acyl chains of unsaturated fatty acids
better than the linear conformations of saturated fatty acids [34].
Even though ATX is the major enzyme that generates LPA, other enzymes have a minor role
in its biosynthesis. For example, saturated LPA species can also be derived through secretory
phospholipase A2, which hydrolyzes phosphatidate in microvesicles that are shed from cells
during inflammation [35] and platelet aggregation [36]. In addition, LPA production by the
Group VIA phospholipase A2 (Ca2+-independent) appears to be involved in the development
of prostate cancers [37].
4. Crystal structure of ATX
The elucidation of the crystal structure of mouse and rat ATX revealed that the enzyme is
composed of four domains [9,34]. The most important among these domains is the slightly U-
shaped catalytic domain, which contains the enzyme’s active site, a hydrophobic pocket and
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hydrophobic channel. Although ATX can hydrolyze both nucleotides and lysophospholipid
substrates, when the unique hydrophobic pocket engages lysophospholipids, nucleotides are
unable to bind to the active site. In addition, lipid acyl chains form further interactions with
this pocket that nucleotides do not, which is also why ATX has a higher affinity for lysophos‐
pholipids [38]. The unique shape of the catalytic domain also accommodates the kinked acyl
chains of unsaturated fatty acids better than the linear conformations of saturated fatty acids
[34], which further explains substrate specificity for ATX.
ATX is the only member of the ENPP enzyme family that contains a hydrophobic pocket for
lysophospholipids, thus giving it a unique capability over other ENPPs. Interestingly, one
amino acid, asparagine 230, is required for ATX to recognize phosphate moieties and produce
lysophosphatidate. Mutating asparagine to alanine inhibited all production. [34] Other single-
point mutations deep within the hydrophobic pocket are capable of altering binding selectivity
and reducing some of ATX’s activity [9].
Perhaps the most exciting biological implication arising from the structural resolution of ATX
is its proposed role as a directed transporter of LPA. In other words, ATX does not appear to
arbitrarily release lysophospholipids from its hydrophobic pocket and channel them into
solution. Rather, ATX is hypothesized to directly transfer LPA to its receptors along the plasma
membrane. The flat surface of ATX on the side of the channel entrance facing the cell presum‐
ably facilitates this purpose [34]. This insinuates a role for ATX as an indirect initiator of cell
signaling through its guided transport of an agonist to its receptor. It also further explains early
observations of ATX as a motility-stimulating factor, even though it was actually due to LPA.
5. ATX Inhibitors
ATX, as an extracellular enzyme, is a very attractive drug candidate for reducing the abun‐
dance of extracellular LPA and subsequent signaling. Indeed, even a transient knockdown of
ATX using siRNA is sufficient to significantly reduce melanoma cell viability [2]. Furthermore,
the advantage of inhibiting ATX is the attenuation of signaling by all LPA receptors. This is
considerably advantageous over the use of individual receptor antagonists because there are
at least six and possibly eight confirmed LPA receptors with extensive redundancy. The design
of ATX inhibitors has been reviewed previously [39-41] and so we will focus only those
inhibitors that show utility in vivo.
Among the first ATX inhibitors was L-histidine, which was reported to have an ATX binding
affinity (Ki) of about 1 mM in vitro, with 10 mM concentrations required to block ATX-
stimulated migration in melanoma cells by 90% [42]. L-histidine inhibits ATX non-competi‐
tively by chelating cations such as Zn2+, which are required for optimum catalytic rates [42].
Later work showed L-histidine administered intraperitoneally to rats limits thioacetamide-
induced liver fibrosis [43]. Although L-histidine is required mM concentrations for activity in
vitro, the authors cited its importance because it was the first “proof-of-principle” that
inhibiting ATX was achievable.
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Few studies have focused on inhibiting ATX transcription. However, one study showed that
cholera toxin inhibits the proliferation of human hepatocellular carcinoma cells in vitro by
suppressing the production of ATX through a TNF-α-dependent mechanism [44]. Cholera toxin
increases the expression of anti-inflammatory cytokines (IL-4 and IL-10), which suppress ATX
mRNA levels [45]. Knockdown of ATX expression with siRNA decreased the effects of cholera-
toxin in suppressing the growth of Hep3B and Huh7 HCC cells [44]. Also, oral administration
of the anti-inflammatory steroid, prednisolone, decreased serum ATX levels in a dose-depend‐
ent manner in patients treated for autoimmune skin diseases [46]. It is uncertain if suppress‐
ing ATX activity contributed to symptom relief since tapering the prednisolone dosage caused
a rebound in serum ATX levels independently of disease severity. Significantly, the authors
proposed that serum ATX levels could be used as a marker of compliance and/or efficacy of
steroid therapy [46]. In addition, rifampicin, which is an inhibitor of DNA-dependent RNA
polymerase, can be used to lower ATX mRNA transcription in the treatment of cholestatic
pruritus. Cessation of rifampicin treatment led to both reoccurrence of pruritus and a re‐
bound of ATX levels to pretreatment levels [47]. All of the treatment options for decreasing ATX
expression appear to be effective in only specific diseases. By contrast, ATX inhibitors are
designed to block LPA production and therefore this approach should have greater utility in
multiple pathologies.
Major criteria for the efficacy of any therapeutic agent is a favorable therapeutic index and
good bioavailability and potency. Reports on competitive ATX inhibitors began around 2006.
These consisted of carba analogs of cyclic phosphatidate (cPA) with a Ki of approximately 100
nM (Table 2). These compounds inhibited metastasis of melanoma cells, which were injected
in the tail vein in mouse models [48] and they inhibited chronic inflammation-induced C-fiber
stimulation in rat neuropathic pain models [49]. However, cyclic phosphatidate analogs are
also weak agonists of LPA receptors, which limits their utility [39].
Compound Class In vivo therapeutic effects
cPA Lipid • inhibits B16F10 melanoma metastasis in mouse tail vein model [48]
• inhibits C-fiber stimulation by chronic inflammation in rat neuropathic pain
models [49]
BrP-LPA Lipid • reduces MDA-MB-231 orthotopic breast tumor growth in mice [50]
• inhibits A549 lung metastasis in engineered 3D mouse xenografts [51]
• radiosensitizes GL-261 mouse glioma models [52]
reduces collagen-induced arthritis in mice [53]
GWJ-A-23 Lipid • reduces allergen-induced asthmatic phenotype in ATX-transgenic mice [54]
• reduces fibrosis in bleomycin-treated mice [55]
PF-8380 Non-Lipid • inhibits inflammatory hyperalgesia in rat air-pouch models [30]
• radiosensitizes glioblastoma multiforme heteotropic mouse models [56]
ONO-8430506 Non-Lipid • reduces tumor growth and metastasis in 4T1/Balb/c syngeneic and
orthotopic mouse model and is synergistic with doxorubicin [33,57]
• reduces urethral tension in rat benign prostatic hyperplasia models [58]
Table 2. ATX inhibitors used to effect a therapeutic response in vivo
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A series of lipid-mimetic ATX inhibitors were developed in 2009 based on α-bromophospho‐
nates (BrP-LPA). The anti-BrP-LPA isomer had IC50 of 22 nM in plasma, which was more potent
than for syn-BrP-LPA [50] (Table 2). BrP-LPA is also a pan-antagonist of LPA1-3, which is
effective in decreasing to tumor growth in orthotopic xenograft models of breast cancer using
MDA-MB-231 cells [50] and in metastasis of A549 lung cancer cells in nude mice [51]. We have
also previously demonstrated that BrP-LPA is more effective than dacarbazine in reducing the
viability of melanoma cells [59].
In addition to its efficacy against cancer cells, BrP-LPA had a radio-sensitizing effect on the
tumor vasculature and delayed tumor growth by 7 days compared to radiation alone in a
heterotopic murine glioma model using GL-261 cells [52]. This study was one of the first to
demonstrate that ATX inhibitors can potential be used as an adjuvant therapy for cancer. A
later report showed that BrP-LPA attenuated disease symptoms by diminishing synovial LPA
signaling in a collagen-induced arthritis mouse model. Histological analysis of the joints
showed a marked decrease in inflammation and synovial hyperplasia [53].
Several lipid-analogs of LPC, which have been used as ATX inhibitors, have relatively poor
bioavailability, mainly because of the hydrophobic acyl tail [41]. This is illustrated by S32826,
which is a benzyl phosphonic acid derivative (Figure 3). Despite having a very low nM IC50 in
vitro, the long chain contributes to a very high lipophilicity and it cannot suppress circulating
ATX activity for more than a few minutes [32]. Analogs of S32826, such as GWJ-A-23, were
developed by shortening the hydrophobic chain and adding α-halo-or α-hydroxy-substituents
to increase solubility. However, most of these compounds are less potent inhibitors of ATX
compared to S32826 [60], but have been used in pulmonary studies of ATX [54,55]. Hence,
much of the recent effort in discovering ATX inhibitors for use in vivo has concentrated on
compounds that are more soluble and not based on lipid analogs.
There are numerous, small, non-lipid inhibitors of ATX that have been modified to increase
potency [40,41]. These inhibitors tend to have better bioavailability because of decreased
hydrophobicity and they are unlikely to be rapidly degraded by endogenous hydrolytic
pathways [61]. One of these is PF-8380, which is a piperazinylbenzoxazolone derivative that
was developed by Pfizer from compound library screening and optimization (Table 2). PF-8380
has an IC50 of 2.8 nM against recombinant human ATX and 101 nM for ATX in human whole
blood. It was the first ATX inhibitor that was reported to decrease plasma LPA levels in vivo
for an extended period [30]. In rat air-pouch models, 30 mg/kg PF-8380 inhibited inflammatory
hyperalgesia with the same efficacy as 30 mg/kg naproxen, a routinely used nonsteroidal anti-
inflammatory drug [30]. This dosage of PF-8380 produced a maximum decrease in LPA
concentrations in plasma and also at the site of inflammation. Like BrP-LPA, PF-8380 had
radio-sensitizing effects in a heterotopic mouse model of glioblastoma multiforme, delaying
tumor growth by at least 20 days [52, 56]. In this study, inhibition of ATX by PF-8380 abrogated
radiation-induced activation of Akt and subsequently decreased tumor vascularity and tumor
growth [56]. Although we have repeatedly tested 30 mg/kg PF-8380 in animal models of
melanoma, we have not observed a reduction of tumor growth (results not shown).
We have worked recently with another potent ATX inhibitor, which is a tetrahydrocarboline
derivative (ONO-8430506) developed by Ono Pharmaceuticals Ltd. (Patent WO20120052227).
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Oral dosing with 10 mg/kg ONO-8430506 suppressed plasma ATX activity as measured by
choline release assay in the presence of 3 mM LPC by at least 90% at 6 h after administration
in mice [33]. Plasma LPA levels were suppressed, especially the unsaturated species. C16:1-
LPA and C20:5-LPA remained non-detectable at 6 and 24 h after ONO-8430506 administration.
ONO-8430506 decreased the initial rate of tumor growth and subsequent lung metastasis by
up to 60% in a syngeneic orthotopic model of breast cancer in BALB/c mice. This was accom‐
panied by decreased concentrations of unsaturated LPA species in the breast tumors. These
findings again confirm that ATX produces most of the extracellular LPA and that decreases in
LPA concentrations in tissues mirror the decreases in plasma LPA levels following ATX
inhibition [30, 33].
In other work, ONO-8430506 (30 mg/kg/day) decreased intra-urethral pressure and this was
ascribed to urethral relaxation [58]. This work demonstrates the potential of ATX inhibition to
decrease smooth muscle contraction by LPA. It also shows that ATX inhibition ameliorates
urethral obstructive disease, such as benign prostatic hyperplasia.
6. Strategies to identify novel ATX inhibitors
So far, the most common technique for ATX inhibitor discovery and design is to screen libraries
of compounds by using assays with ATX substrates such as Fluorescent Substrate-3 (FS-3).
Inhibitors are then modified to increase potency. FS-3 is a fluorogenic substrate that is a doubly-
labeled analogue of LPC. The fluorophore is quenched through intra-molecular energy
transfer. Hydrolysis of FS-3 by ATX increases the fluorescent signal by removing the quencher
[62]. The initial studies with this technique identified several inhibitors with an IC50 in the µM
range [63, 64]. Later work with compounds designed from these studies developed nine
pharmacophores for ATX inhibition and the results of these analyses were used to screen the
National Cancer Institute’s open chemical repository database to prioritize screening efforts
[61]. This lead to the identification of several novel compounds with an IC50 in the high to low
µM range [61, 65].
The identification of the crystal structure of ATX is also enabling structure-activity relation‐
ships to be established and more rational-design approaches towards optimizing inhibitor
structures are now possible. The first study to report this approach was by Kawaguchi et al.
who identified a thiazolone derivative from a 81,600-compound library, which inhibited ATX
activity with an IC50 of 180 nM [66]. The authors proposed a series of side-chain modifications
from the crystal structure of ATX complexed with this inhibitor. This led to the synthesis of a
derivative compound, 3BoA, which has an IC50 of 13 nM [66]. More recent studies by Fells et
al. combined large library screening results using the crystal structure of ATX with virtual
screening tools to discover additional novel ATX inhibitors [67, 68]. This technique identified
a common aromatic sulfonamide structural motif among potent inhibitors that targets the
hydrophobic pocket of ATX. This accommodates the hydrocarbon tail of LPC/LPA [67, 68].
Similar techniques are expected to lead to the rapid development of ATX inhibitors for
subsequent testing and development in vivo.
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7. Physiological functions of ATX and LPA signaling
7.1. Vasculature system
Although studies in vitro detected no difference in the growth rate of ras-transformed NIH3T3
cells with or without ATX in culture, the growth rates in animals were significantly different,
which suggested a role for ATX in blood vessel formation [21]. Indeed, Matrigel plugs of cells
with ATX displayed extensive micro-aneurysms filled with red blood cells and more tumor
cells, further corroborating this role. Furthermore, the ability of ATX to stimulate blood vessel
formation in Matrigel plugs after 6 days was equivalent to VEGF, thus solidifying ATX as an
angiogenesis-stimulating factor in the circulation [69].
Developmentally, the expression of ATX is indispensible. Beginning at 8.5 days, ATX expres‐
sion is detectable in the early mouse embryo, within the floor plate of the neural tube [70].
Knocking out of ATX in mice causes embryonic lethality around 9.5 – 10.5 days with embryos
exhibiting open, kinky neural tubes [28,71]. Although heartbeats are detected until 10.5 days
in utero, contractions are weak, irregular and clearly abnormal. In addition, even the yolk sacs
of ATX knockout embryos are irregular with a complete absence of blood vessels. [72] The role
of ATX in vascular and neural development is also observed in zebrafish [72, 73]. ATX regulates
the differentiation of oligodendrocytes in the hindbrain [74] and the correct left-right asym‐
metry for normal organ morphogenesis through Wnt-dependent pathways [75]. Taken
together, these results definitively prove that the absence of ATX results in severe defects of
the vasculature system and embryonic lethality. Organisms cannot develop without functional
ATX expression.
Other groups have explored the parallel correlation by investigating the vasculature system
when ATX is overexpressed in transgenic mice. Interestingly, ATX transgenic mice have an
unusual susceptibility to bleeding and impaired platelet-dependent thrombus formation after
injury [10]. Further studies have confirmed an important role for ATX in platelet activation
through the production of LPA [76]. In addition, ATX binds to platelet β1-and β3-integrins,
which localizes ATX to the cell surface of the appropriate microenvironment [11].
8. Adipose tissue regulation
An alternative, yet highly interesting function of ATX in vivo occurs in adipogenesis, obesity
and the regulation of glucose homeostasis [77]. Foremost, ATX is expressed and secreted by
adipose tissue. Its expression is also significantly upregulated during pre-adipocyte differen‐
tiation into adipocytes (adipogenesis) as well as in the adipose tissue of genetically obese
diabetic mice [78]. In support of this finding, transgenic ATX mice accumulate more fat than
littermates when they are fed a high-fat diet and thus, are more susceptible to diet-induced
obesity [79]. Other work showed that ATX mRNA is upregulated in differentiating adipocytes
but downregulated in hypertrophied adipocytes from obese mice [80]. Further, in humans,
serum ATX levels and ATX mRNA expression in subcutaneous fat were negatively correlated
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with body mass index [80]. However this does not appear to be true if the subject is diabetic.
Instead, these patients tend to have higher serum ATX levels [80]. In regards to the regulation
of glucose metabolism, LPA produced by ATX is able to dose-dependently inhibit glucose-
induced insulin secretion [77, 81]. Furthermore, knocking out the expression of ATX in adipose
tissue results in a mouse with improved glucose tolerance [82].
9. Wound healing, tissue remodeling and inflammation
ATX and LPA facilitate critical processes necessary for skin re-epithelialization and wound
healing. For example, among blister fluids, both ATX and LPA are produced and detected,
originating de novo in the blister fluid and not from plasma. LPA is a potent activator of platelet
aggregation and promotes keratinocyte migration, proliferation and differentiation. Thus,
ATX and LPA facilitate critical processes necessary for skin re-epithelialization and wound
healing [83]. ATX expression and LPA production are increased in rabbit aqueous humor
following wounding by corneal freezing [84].
The range of physiological functions requiring ATX is quite diverse. For example, ATX and LPA
signaling are involved in luteal tissue remodeling of regressing corpora lutea in rat ovaries. This
occurs by recruiting phagocytes and proliferating fibroblasts, which are ultimately the factors
involved in remodeling [85]. Other roles for ATX include hair follicle morphogenesis [86], bone
mineralization [87] and myeloid differentiation in human bone marrow [88].
Another unique role of ATX occurs in response to oxidative stress in microglia, whereby ATX
expression is increased. This protects microglia cells from damage by H2O2 and this effect is
partially reversed by the mixed LPA1/3 antagonist, Ki16425 [89]. Microglia cells overexpressing
ATX show suppressed production of the pro-inflammatory cytokines, TNF-α and IL-6, and
increases in the anti-inflammatory cytokine IL-10 upon treatment with lipopolysaccharide [90].
ATX is expressed in high endothelial venules in lymph nodes and other secondary lymphoid
tissues [91]. This mediates lymphocyte extravasation, a process required for maintaining
immune homeostasis [92, 93]. However, in chronically inflamed tissues, ATX mediates
lymphocyte trafficking and increases cytokine production in response to repeated micro-
injuries and incomplete tissue repair [94-96].
Interestingly, the catalytic activity of ATX has a dualistic role in wound healing. In this way,
an ATX-like enzyme, SMaseD, is responsible for the pathology associated with venomous
poisons through its dermonecrotic and hemolytic activities [97, 98]. In other words, the
aberrant over-production of LPA by ATX cultivates an inappropriate immune response,
similar to a wound that never heals, whereby overabundant inflammatory cytokines and
chemokines are released. The damage is manifested in several ways, including the presence
of severe dermonecrosis with blackened or missing skin appearing at the wounded site. The
dermonecrosis can occur after envenomation by either Loxosceles reclusa, the brown recluse
spider [97], or Hemiscorpius lepturus, a venomous scorpion [98]. Intriguingly, susceptibility to
SMaseD is conferred by the LPA1 receptor [99], suggesting a possible role for LPA receptor
antagonists in this pathology.
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As mentioned above, one of the main functions of ATX in adults is to repair damaged tissue.
ATX is secreted in this situation partly in response to inflammation and the release of inflam‐
matory cytokines. In normal wound healing, the production of LPA by ATX causes cells to
migrate into the area of damage to effect wound repair and the formation of new blood vessels.
In cases where the inflammation is not resolved, the process can result in tissue damage and
fibrosis as in rheumatoid arthritis, atherosclerosis, organ fibrosis, diabetes and even obesity
[100]. Cancer can be added to this list since it has been likened to “a wound that does not heal”
[101]. The role of inflammatory cytokines in tumor progression [102-106] explains why
inflammatory bowel disease and viral hepatitis can progress to cancer [107].
10. ATX in malignancy: Metastasis and angiogenesis
ATX is among the top 40 upregulated genes in metastatic cancer [108] and this is explained by
the effects of LPA, which signals through at least six and putatively eight G-protein-coupled
receptors. Through these receptors, LPA stimulates cell motility, cell survival/viability, cell
proliferation, morphological changes, contraction, wound healing and invasion [109-118]. LPA
achieves these effects by signaling through the relative activations of phosphatidylinositol 3-
kinase (PI3K), ERK1/2, mTOR, Ca2+-transients, Rac, Rho and Ras [119].
The involvement of ATX and LPA in tumor progression affects multiple malignant processes
and stages of tumor progression. For example, LPA increases the production of vascular
endothelial growth factor, which stimulates angiogenesis [51, 120], a process required for
tumor growth beyond 1 mm. However, in order for tumors to arise at all, tumor suppressors
must be made ineffective. LPA levels can rise to 10 µM in the ascites fluid from advanced
ovarian cancer patients [121]. Interestingly, LPA also decreases the abundance of the tumor
suppressor, p53 [122], thus increasing cancer cell survival and proliferation, even in the
presence of actinomycin D.
Pre-clinical models of disease and clinical pathology provide insight into the role of ATX and
LPA receptors in cancer. For example, transgenic multiparous mice designed to overexpress
ATX, LPA1, LPA2 or LPA3 in mammary epithelium develop spontaneous metastatic mammary
tumors as they age [123]. Women who express high levels of LPA3 receptors in epithelial cells,
or ATX in stromal cells, have larger breast tumors, nodal involvement, and higher stages of
disease [124]. Since many early stage breast cancer patients are able to be cured using current
treatment modalities, this suggests that the presence of ATX and/or LPA receptors has the
ability to alter outcomes of malignancy.
The involvement of ATX and LPA in tumor progression can be understood in terms of a
dysfunctional wound healing response. As mentioned above, one of the main functions of ATX
in adults is to repair damaged tissue. ATX is secreted in this situation partly in response to
inflammation and the release of inflammatory cytokines. In normal wound healing, the
production of LPA by ATX causes cells to migrate into the area of damage to effect wound
repair and the formation of new blood vessels. Cancer can be considered to be a case of
unresolved inflammation and it has been likened to “a wound that does not heal” [101]. In
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fact, inflammation is now considered to be one of the “Hallmarks of Cancer” [125]. The
secretion of ATX and increased LPA signaling should now be included as one of the inflam‐
matory factors that drives tumor progression.
The role of ATX and LPA in this process is well illustrated in the case of work with mouse
models of breast cancer. Most breast cancer cells do not themselves express ATX, but rather
this is produced by fibroblasts within the breast tissue or by the surrounding adipose tissue
[33] (Figure 3). The development of the breast tumor causes the release of inflammatory
cytokines, which stimulate fibroblasts and adipose tissue to secrete ATX in a syngeneic
orthotopic mouse model of breast cancer [33, 107]. This is part of a vicious cycle since LPA in
turn stimulates the production of inflammatory cytokines [126-128]. This inflammatory cycle
can be effectively blocked in a mouse by inhibiting ATX activity with ONO-8430506, which
results in about a 60% decrease in tumor growth and lung metastasis.
Figure 3. Proposed inflammatory-mediated models of ATX secretion. A) In cancer cells that overexpress ATX such as
thyroid cancers, neuroblastomas and melanomas, autocrine-secreted ATX produces LPA, which signals through LPA re‐
ceptors (LPARs) on the cancer cell surface. This signaling further increases the production of pro-inflammatory signals in‐
cluding growth factors, cytokines and chemokines. These molecules in turn can signal through specific receptors to
increase ATX production. B) In breast cancer, a paracrine model of ATX secretion is possible since breast adipose tissue se‐
cretes high levels of ATX, whereas breast cancer cells normally produce negligible ATX. As the tumor grows, pro-inflam‐
matory signals secreted by the tumor create an inflammatory environment within the surrounding adipose tissue (green
arrows). This signaling increases ATX secretion and LPA production, which in turn can establish an autocrine feedback
loop of increased pro-inflammatory signaling and ATX production (red arrows) within the adipose tissue. Increased ATX
and LPA production can in turn contribute to tumor progression (green arrows). A combination of both autocrine and
paracrine production of ATX is also possible when cancer cells produce significant quantities of ATX.
Although breast cancer cells do not do not express significant levels of ATX activity, this is not
typical of other tumors where ATX activity is expressed in the cancer cells themselves. These
cancers include thyroid [129], neuroblastomas [71, 130, 131] and melanomas [132-134].
However, in the case of melanomas, their normal predecessor cells, melanocytes, do not
express ATX. Thus, the data suggests that ATX expression is acquired during the transition to
malignancy in melanoma [2]. The secretion of inflammatory cytokines by cells in the tumor
also produces a vicious cycle of ATX secretion and LPA production, which is a driving force
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in tumor progression [107]. In the case of breast tumors, we propose that the ATX come from
surrounding adipose tissue, whereas in thyroid tumors, neuroblastomas and melanomas, ATX
is secreted by the cancer cells (Figure 3).
11. ATX in chemo-resistance
Another important role of ATX expression and LPA signaling in malignancy occurs during
the acquisition and manifestation of chemo-resistance. LPA facilitates chemo-resistance to the
cytotoxic effects mediated by Taxol [119, 135, 136], doxorubicin [57], actinomycin D [122] and
carboplatin [137]. These effects are mediated by LPA partly through activation of survival and
viability pathways, such as ERK and PI3K. In addition, we previously demonstrated that LPA
signaling does not encompass the entire molecular mechanism and there are other proteins,
like the Regulators of G-protein Signaling proteins, which play a more dominant role [138].
Indeed, in the absence of appropriate Regulators of G-protein Signaling proteins, cells exposed
to LPA have increased capacity to acquire chemo-resistance.
As chemo-resistance is a complex process, there are other molecular mechanisms involved.
For example, among chemo-resistant cells, increased expression of multidrug resistance
transporters enables toxins, like chemotherapeutic drugs, to be exported out of cancer cells.
This is particularly problematic in the case of renal cell carcinomas, for which cytotoxic
chemotherapy is largely ineffective, but also occurs widely in malignancy.
Recent work shows that the activation of PI3K by through LPA1 receptors increases the stability
of the transcription factor Nrf2, which increases the expression of antioxidant genes and
multidrug resistant transporters [57]. The expression of antioxidant genes protects cancer cells
against the oxidative damage caused by chemotherapeutic agents. Also, the expression of
multidrug resistant transporters enables toxic oxidative products and chemotherapeutic drugs
to be exported out of cancer cells. These effects explain why inhibiting ATX activity and
blocking LPA signaling improves the efficacy of doxorubicin as a chemotherapeutic agent [57].
Thus blocking ATX activity can provide a novel adjuvant therapy for improving the efficacy
of existing chemotherapeutic agents.
ATX inhibition could also have a beneficial effect as an adjuvant for improving the effects of
radiotherapy as discussed above. This is possible since LPA, through activation of LPA2
receptors, also protects against radiation-induced cell death. This action depends on the
depletion Siva-1, which is a pro-apoptotic signaling protein [139].
The function of ATX in aggravating resistance to chemotherapy and radiotherapy can be
understood in terms of the vicious cycle of inflammation caused by repeated bouts of therapy
as described above [140] (Figure 3). Cancer therapy itself causes damage to the tumor and
surrounding tissue, which responds by producing inflammatory cytokines resulting in
increased ATX production [107]. This explains why blocking this cycle by inhibiting LPA
formation can improve the sensitivity to chemotherapy by attenuating the effects of increased
Nrf2 expression.
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12. ATX in melanoma
Although accumulating studies suggest that inhibiting ATX activity could provide a novel
adjuvant therapy for improving the efficacy of existing chemotherapeutic agents, we have
previously demonstrated a role for ATX inhibitors as monotherapy against advanced cutane‐
ous melanoma [2,48,59]. After injecting B16F10 metastatic melanoma cells into the tail veins of
C57/Bl6 mice, we observed a significant reduction in the number of lung nodules, which
represent metastatic melanoma tumors, after treatment with a phosphonothionate analogue of
carba cyclic phosphatidic acid, thio-ccPA 18:1 [2]. This compound was synthesized for im‐
proved metabolic stability and activity, based on our previous results [48]. In addition to being
an inhibitor of ATX, thio-ccPA 18:1 is a direct antagonist of LPA1 and LPA3 receptors [141].
As mentioned previously, melanomas are notoriously resistant to chemotherapy. In light of
the role of ATX/LPA signaling in melanoma, perhaps it should not be surprising that mela‐
noma cells, which produce high quantities of ATX, are resistant to chemotherapy, since
excessive LPA signaling contributes to this phenotype. Only a few chemotherapy agents are
approved options against melanoma, these include dacarbazine and temozolomide. Thus, we
compared these single agents against both the anti-BrP-LPA and the mixed diastereomers BrP-
LPA on the viability of MeWo melanoma cells. Indeed, both BrP-LPA compounds were more
effective single-agents at 10 µM and 100 µM than either dacarbazine or temozolomide, at
concentration ranging from 10-1000 µM [59]. This suggests that targeted approaches against
ATX in melanoma have potential and further results will be reported in due time.
Besides cutaneous melanoma, in a study on uveal melanoma, ATX was the only gene among
32 candidate genes whose expression was sufficient to distinguish classes representing
metastasis and prognosis. Paradoxically, “underexpression” of ATX correlated with poor
prognosis and metastatic death among 27 samples [132]. Based on the discussion provided
above it is tempting to propose that melanocytes evolved to survive solar ultraviolet radiation
and simultaneously provide protection to neighboring cells by producing ATX and thus
providing LPA. However, with repeated DNA damage and incomplete repair from excessive
UV radiation, melanocytes are malignantly transformed into melanoma cells. At this point,
the increased production of ATX and signaling by inflammatory cytokines, which are meant
to facilitate repair, could be subverted into promoting cancer progression.
13. Summary and conclusions
Advanced metastatic melanoma is an incurable disease in dire need of additional therapeutic
options. Although many newly targeted inhibitors have extended the life of patients with
BRAF mutations, they do not achieve cure due to chemo-resistance, and they are not applicable
to patients with Wild-type B-Raf. Thus, additional therapeutics are desperately needed to treat
this growing population. Herein we have summarized the current state of ATX inhibitors and
what we currently know about the role of ATX in melanoma and malignancy.
The original ATX inhibitors had little utility in vivo because of the very low bioavailability.
However, as described above, potent ATX inhibitors are now being developed, which are
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effective in vivo for longer than 24 h. These inhibitors appear to be well tolerated by animals
and the next stage is to take such inhibitors through Phase 1 clinical trials. These ATX inhibitors
should be effective in improving the outcomes for which the ATX/LPA axis is involved. These
include various forms of cancer whereby an ATX inhibitor could be used as a monotherapy
or as an adjuvant to improve existing chemotherapies or radiation treatment. The ATX
inhibitors should also be effective in improving the treatment of a variety of inflammatory
conditions. These compounds deserve further examination.
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